Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

Over the last several quarters, we have had a series of interactions with the agency focused on our ... In addition to our complement antibodies, narsoplimab, zaltenibart and OMS1029, we continue ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...